α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
详细信息 查看全文
- 作者：Yasuto Akiyama (1)
Chie Oshita (1)
Akiko Kume (1)
Akira Iizuka (1)
Haruo Miyata (1)
Masaru Komiyama (1)
Tadashi Ashizawa (1)
Mika Yagoto (1)
Yoshiaki Abe (4)
Koichi Mitsuya (2)
Reiko Watanabe (3)
Takashi Sugino (3)
Ken Yamaguchi (1)
Yoko Nakasu (2) - 关键词：Dendritic cell ; Immunotherapy ; High ; grade glioma ; HLA ; A24 ; Phase I trial
- 刊名：BMC Cancer
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：401KB
- 参考文献：1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, / et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. / N Engl J Med 2005,352(10):987-96. CrossRef
2. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, / et al.: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. / J Clin Oncol 2006,24(16):2563-569. CrossRef
3. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K: Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. / Cell Stem Cell 2009,5(5):504-14. CrossRef
4. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN: Therapeutic potential of AZD1480 for the treatment of human glioblastoma. / Mol Cancer Ther 2011,10(12):2384-393. CrossRef
5. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, / et al.: Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. / J Neurooncol 2012,107(3):487-01. CrossRef
6. Ball S, Li C, Li PK, Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. / PLoS One 2011,6(4):e18820. CrossRef
7. Zhou Y, Liu F, Xu Q, Wang X: Analysis of the expression profile of dickkopf-1 gene in human glioma and the association with tumor malignancy. / J Exp Clin Cancer Res 2010, 29:138. CrossRef
8. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, / et al.: Randomized phase II study of cilemgitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. / J Clin Oncol 2008,26(34):5610-617. CrossRef
9. Jo J, Schiff D, Purow B: Angiogenic inhibition in high-grade gliomas: past, present and future. / Expert Rev Neurother 2012,12(6):733-47. CrossRef
10. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK: A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. / J Clin Neurosci 2011,18(8):1048-054. CrossRef
11. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, / et al.: Intergation of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. / Cancer Immunol Immunother 2012,61(11):2033-044. Apr 22 CrossRef
12. Yamanaka R: Cell- and peptide-based immunotherapeutic approaches for glioma. / Trends Mol Med 2008,14(5):228-35. CrossRef
13. Luptrawan A, Liu G, Yu JS: Dendritic cell immunotherapy for malignant gliomas. / Rev Recent Clin Trials 2008,3(1):10-1. CrossRef
14. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, / et al.: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. / J Neurooncol 2010,99(2):261-72. CrossRef
15. Cheever MA, Higano CS: PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. / Clin Cancer Res 2011,17(11):3520-526. CrossRef
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, / et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. / N Engl J Med 2010,363(5):411-22. CrossRef
17. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P: α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. / Cancer Res 2004,64(17):5934-937. CrossRef
18. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, / et al.: Induction of CD8+T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. / J Clin Oncol 2011,29(3):330-36. CrossRef
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: / WHO classification of tumours of the central nervous system. 4th edition. Lyon: IARC; 2007.
20. Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, / et al.: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. / J Transl Med 2005.,3(1):
21. Ferrari S, Malugani F, Rovati B, Porta C, Riccardi A, Danova M: Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. / Oncol Rep 2005,14(1):113-20.
22. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K: Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. / Anticancer Res 2004,24(2B):571-77.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, / et al.: New guidelines to evaluate the response to treatment in solid tumors. / J Natl Cancer Inst 2000,92(3):205-16. CrossRef
24. Gardner TA, Elzey BD, Hahn NM: Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. / Hum Vaccin Immunother 2012,8(4):534-39.
25. Lubaroff DM: Prostate cancer vaccines in clinical trials. / Expert Rev Vaccines 2012,11(7):857-68. CrossRef
26. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. / Cancer Res 2004,64(14):4973-979. CrossRef
27. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van LJ, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, / et al.: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. / Clin Cancer Res 2008,14(10):3098-104. CrossRef
28. Wheeler CJ, Black KL: DCVax-brain and DC vaccines in the treatment of GBM. / Expert Opin Investig Drugs 2009,18(4):509-19. CrossRef
29. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiokowski ZM, Tosteson TD, Rhodes CH, Wishart HA, / et al.: Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. / J Immunother 2011,34(4):382-89. CrossRef
30. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, / et al.: Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. / Cancer Res 2009,69(4):1587-595. CrossRef
31. Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G: Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. / J Transl Med 2011,14(9):198. CrossRef
32. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejiani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, / et al.: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. / J Transl Med 2007, 5:67. CrossRef
33. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, / et al.: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. / Cancer Res 2007,67(4):1842-852. CrossRef
34. Szmania S, Yi Q, Cottler-Fox M, Rosen NA, Freeman J, Kordsmeier BJ, Moreno A, Shi J, Barlogie B, Tricot G, / et al.: Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation. / Cytotherapy 2005,7(4):374-84. CrossRef
35. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, / et al.: Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. / Oncol Rep 2012,28(4):1131-138.
36. Wheeler CJ, Das A, Liu G, Yu JS, Black KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. / Clin Cancer Res 2004,10(16):5316-326. CrossRef
37. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/623/prepub - 作者单位：Yasuto Akiyama (1)
Chie Oshita (1)
Akiko Kume (1)
Akira Iizuka (1)
Haruo Miyata (1)
Masaru Komiyama (1)
Tadashi Ashizawa (1)
Mika Yagoto (1)
Yoshiaki Abe (4)
Koichi Mitsuya (2)
Reiko Watanabe (3)
Takashi Sugino (3)
Ken Yamaguchi (1)
Yoko Nakasu (2)
1. Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
4. Division of blood stem cell transplantation, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Shizuoka, 411-8777, Japan
2. Division of Neurosurgery, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Shizuoka, 411-8777, Japan
3. Division of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Shizuoka, 411-8777, Japan - ISSN：1471-2407
文摘
Background High-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and aggressive of tumors, and have a very poor prognosis despite a temozolomide-based intensive treatment. Therefore, a novel therapeutic approach to controlling recurrence is needed. In the present study, we investigated the effect of activated dendritic cell (DC) (α-type-1 polarized DC)-based immunotherapy on high-grade glioma patients with the HLA-A2 or A24 genotype. Methods Nine patients with recurrent high-grade gliomas including 7 with GBMs who fulfilled eligibility criteria were enrolled into a phase I study of monocyte-derived DC-based immunotherapy. HLA-genotyping revealed 1 case of HLA-A*0201 and 8 cases of A*2402. Enriched monocytes obtained using OptiPrepTM from leukapheresis products on day1, were incubated with GM-CSF and IL-4 in a closed serum-free system, and activated on day6 with TNF-α, IL-1β, IFN-α, IFN-γ, and poly I/C. After pulsing with a cocktail of 5 synthetic peptides (WT-1, HER2, MAGE-A3, and MAGE-A1 or gp100) restricted to HLA-A2 or A24 and KLH, cells were cryopreserved until used. Thawed DCs were injected intradermally in the posterior neck at a dose per cohort of 1.0, 2.0 and 5.0× 107/body. Results The frequency of CD14+ monocytes increased to 44.6% from 11.9% after gradient centrifugation. After a 7-day-incubation with cytokines, the mean percentage of DCs rated as lin-HLA-DR+ in patients was 56.2 ± 19.1%. Most DCs expressed high levels of maturation markers, co-stimulatory molecules and type-1 phenotype (CD11c+HLA-DR+) with a DC1/2 ratio of 35.6. The amount of IL-12 produced from activated DCs was 1025 ± 443 pg/ml per 105 cells. All 76 DC injections were well tolerated except for transient liver dysfunction with grade II. Six patients showed positive immunological responses to peptides in an ELISPOT assay, and positive skin tests to peptide-pulsed DC and KLH were recognized in 4 cases. The clinical response to DC injections was as follows :1 SD and 8 PD. Interestingly, the SD patient, given 24 DC injections, showed a long-term recurrence-free and immunological positive response period. Conclusions These results indicate peptide cocktail-treated activated α-type-1 DC-based immunotherapy to be a potential therapeutic tool against recurrent high-grade glioma with mainly HLA-A*2402. Trial registration Current non-randomized investigational trial UMIN-CTR UMIN ID: 000000914.